Phase 2 Rectal Cancer trials recruiting now

All Rectal Cancer trials, every phase

Other phases for Rectal Cancer

Phase 2 Rectal Cancer trials

• A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer
  NCT05939661 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
  NCT05024097 · Phase: Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 3 locations
• A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
  NCT07239466 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
  NCT07227636 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
  NCT07011576 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
  NCT05672524 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
  NCT06682793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
  NCT06051695 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer
  NCT06765616 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
  NCT03190941 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · 2 locations
• CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
  NCT06006390 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC
  NCT07646639 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
  NCT06239194 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria
  NCT07505472 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer
  NCT07108127 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II and III Rectal Cancer Patients
  NCT07095439 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
  NCT03516708 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
  NCT06923345 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
  NCT04109755 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer
  NCT05450029 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer
  NCT06718543 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
  NCT06958432 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy
  NCT07337876 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
  NCT07292298 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 3 locations
• Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer
  NCT05136326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)
  NCT06770270 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
  NCT07162714 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
  NCT07198165 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
  NCT05576480 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
  NCT07284992 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
  NCT05806931 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
  NCT07594925 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
  NCT06542588 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
  NCT06455124 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
  NCT04636008 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
  NCT07104604 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
  NCT06254521 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
  NCT04643366 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
  NCT06758830 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Total Neoadjuvant Therapy in Rectal Cancer
  NCT06162650 · Phase: Phase 2 · Ages: 20 Years and older · Sex: All (male and female) · 1 location
• Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
  NCT05965531 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
  NCT05254327 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.